Comparing the ability of freshly generated and cryopreserved dendritic cell vaccines to inhibit growth of breast cancer in a mouse model

BioResearch Open Access

Volumn 1, Issue 5, 2012, Pages 239-246

  Radhakrishnan, Ammu Kutty ^a   Sim, Geok Choo ^a   Cheong, Soon Keng ^b  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^b UNIVERSITI TUNKU ABDUL RAHMAN   (Malaysia)

Author keywords

Cryopreservation; Dendritic cells; DNDC; Tumor immunotherapy

Indexed keywords

DENDRITIC CELL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CELL LINE; CELL LYSATE; CELL PROLIFERATION; CELL STRUCTURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; CRYOPRESERVATION; DENDRITIC CELL; FEMALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 84881281957     PISSN: None     EISSN: 21647860     Source Type: Journal    
DOI: 10.1089/biores.2012.0229     Document Type: Article

References (23)

1. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med. 1973;137: 1142-1162.
2. Banchereau J, Brier F, Caus C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811.
3. Feng B, Inaba M, Lain ZX, et al. Development of mouse dendritic cells from lineage-negative c-kit < low pluripotent hemopoietic stem cells in vitro. Stem Cells. 2000;18:53-60.
4. Hochrein H, Shortman K, Vremec D, et al. Differential production of IL-12, IFN-alpha, and IFN-gamma by mouse dendritic cell subsets. J Immunol. 2001;166:5448-5455.
5. Lanzavecchia A. Mechanisms of antigen uptake for presentation. Curr Opin Immunol. 1996;8:348-354.
6. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA. 1998;95:9482-9487.
7. Shimizu K, Fields R, Gieedlin M, Mule JJ. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci USA. 1999;96:2268-2273.
8. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotypepulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. Blood. 2002;99: 1517-1526.
9. Brody JD, Engleman EG. DC-based cancer vaccines: Lessons from clinical trials. Cytotherapy. 2004;6:122-127.
10. Banchereau J, Ueno H, Dhodapkar M, et al. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34 + progenitors and activated with type I interferon. J Immunother. 2005;28:505-516.
11. Panelli MC, Wunderlich J, Jeffries J, et al. Phase 1 study in patientswith metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanomaassociated antigens MART-1 and gp100. J Immunother. 2000;23:487-498.
12. O'Rourke MG, Johnson M, Lanagan C, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother. 2003;52:387-395.
13. Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: Update of the MDACC series. Ann Oncol. 2000;11:137-140.
14. Tjoa BA, Simmons SJ, Elgamal A, et al. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate. 1999;40: 125-129.
15. Candido KA, Shimizu K, McLaughlin JC, et al. Local administration of dendritic cells inhibits established breast tumor growth: Implications for apoptosis-inducing agents. Cancer Res. 2001;61:228-236.
16. John J, Hutchinson J, Dalgleish A, Pandha H. Cryopreservation of immature monocyte-derived dendritic cells results in enhanced cell maturation but reduced endocytic activity and efficacy of adenoviral transduction. J Immunol Methods. 2003;272:35-48.
17. Westermann J, Korner IJ, Kopp J, et al. Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: Influence on phenotype and functional properties. Cancer Immunol Immunother. 2003;52:194-198.
18. Feuerstein B, Berger TG, Maczek C, et al. A method of the production of cryopreserved aliwouts of antigen-preloaded mature dendritic cells ready for clinical use. J Immunol Methods. 2000;245:15-29.
19. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med. 2002;195:1279-1288. Erratum in: J Exp Med. 2003; 197:395.
20. Pulaski BA, Terman DS, Khan S, et al. Cooperatively of Staphylococcal aureus Enterotoxin B Superantigen, major histocompability complex Class II, and CD80 for Immunotherapy of Advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res. 2000;60:710-2715.
21. Inaba K, InabaM, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176:1693-1702.
22. Hori S, Heike Y, Takei M, et al. Freeze-thawing procedures have no influence on the phenotypic and functional development of dendritic cells generated from peripheral blood CD14 + monocytes. J Immunother. 2004;27:27-35.
23. Dunn GP, Bruce AP, Ikeda H, et al. Cancer immunoediting from iimune surveillance to tumour escape. Nat Immunol. 2002;4:1206-1212.